Funding News Edition: August 18, 2021 See more articles in this edition
Small businesses are invited to submit research proposals in response to A Solicitation of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals published on July 30, 2021.
Proposals are due by October 28, 2021 at 5 p.m. Eastern Time.
If you missed the August 12 webinar about the solicitation, check for a video recording and webinar slides on NIH’s Engage & Connect webpage.
Note: This SBIR contract solicitation is separate from the recently issued 2021 SBIR and STTR Omnibus/Parent Grant Solicitations for the NIH, CDC, and FDA, which are funding opportunity announcements for grant awards (despite the word “solicitation” appearing in the titles). Learn more about those grant opportunities in the August 4, 2021 article “Explore Topics for 2021 Small Business Omnibus Grants.”
The table below offers a brief summary of each of NIAID’s research topics of interest for contract proposals. Refer to the attachment posted within the solicitation linked above for full details.
| Topic Number and Title | Project Goal | Budget (Total Costs) |
|---|---|---|
|
101. Novel Platforms for Delivery and/or Expression of HIV Env Immunogens for HIV Vaccines |
To develop an HIV vaccine platform for delivery of HIV envelope (Env) immunogens that induce broadly neutralizing antibodies (bNAbs) and demonstrate that the vaccine platform/immunogen proposed will elicit a strong and durable NAb HIV Env response. |
Phase I: $300,000 for up to one year Phase II: $2 million for up to three years |
|
102. Genetically Engineered Mice for Preclinical Evaluation of HIV Vaccine Candidates |
To utilize genetically engineered mouse models, such as human immunoglobulin knock-in or other transgenic mice expressing relevant human genes, to accelerate testing and development of HIV vaccine candidates. |
Phase I: $300,000 for up to one year Phase II: $2 million for up to three years |
|
103. Development of Diagnostics to Differentiate HIV Infection from Vaccine Induced Seropositivity |
To support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced sero-positivity, with high sensitivity and specificity. |
Phase I: $300,000 for up to one year Phase II: $2 million for up to three years |
|
104. Adjuvant Discovery for Vaccines and for Autoimmune and Allergic Diseases |
To support the screening for new adjuvant candidates for vaccines against infectious diseases, or for autoimmune and allergic diseases, or transplantation; their characterization; and early-stage optimization. |
Phase I: $300,000 each year for up to two years Phase II: $1 million each year—with appropriate justification—for up to three years |
|
105. Adjuvant Development for Vaccines and for Autoimmune and Allergic Diseases |
To support the preclinical development of novel vaccine adjuvants for use in vaccines against infectious diseases or of tolerogenic adjuvants for the treatment of immune-mediated diseases. |
Phase I: $300,000 each year for up to two years Phase II: $1 million each year—with appropriate justification—for up to three years |
|
106. Production of Adjuvants Mimics |
To develop, validate, and produce adjuvants that are based on, or similar to, compounds or formulations previously successfully used in clinical trials, for use by the broader research community, either as commercial products or through licensing agreements. |
Phase I: $300,000 each year for up to two years Phase II: $1 million each year—with appropriate justification—for up to three years |
|
107. Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models |
To develop and validate reliable antibodies and reagents for identifying and tracking immune cells or the analysis of immune function/responses (e.g., cytokines, chemokines, intracellular signaling) in non-mammalian models or underrepresented mammalian models. |
Phase I: $300,000 each year for up to two years Phase II: $1.5 million—with appropriate justification—for up to three years |
|
108. Development of Rapid Point-of-Care (POC) Diagnostics for Treponema pallidum |
To develop a rapid (less than one hour), POC diagnostic capable of detecting Treponema pallidum directly from patient specimens. |
Phase I: $300,000 each year for up to two years Phase II: $1.5 million—with appropriate justification—for up to three years |
|
109. Development of Monoclonal Antibody-Mediated Interventions To Combat Malaria |
To develop monoclonal antibody (mAb) or mAb-based candidates for malaria prevention or treatment. |
Phase I: $300,000 for up to two years Phase II: $1.5 million for up to three years |
|
110. POC Diagnostics for Antimicrobial Resistant (AMR) Enteric Bacterial and Parasitic Pathogens |
To develop a rapid (less than one hour), POC diagnostic capable of detecting infectious enteric pathogens (two or more) and associated antimicrobial resistance profile(s) directly from patient specimens (e.g., stool samples). |
Phase I: $300,000 for up to one year Phase II: $1.5 million for up to three years |
|
111. Data Science Tools for Infectious and Immune-Mediated Disease Research |
To support the new development of innovative, robust informatics/data science tools, or enhancement or adaptation of existing tools for use in infectious, immune, and allergic diseases. |
Phase I: $300,000 for up to one year Phase II: $1 million for up to three years |
|
112. Digital Tools Against Misinformation About Infectious Disease Treatments and Vaccines |
To develop digital tools to identify and combat malicious digital bots that spread misinformation about infectious disease treatments and vaccines. |
Phase I: $300,000 for up to one year Phase II: $1 million for up to three years |
Direct your technical questions about the solicitation and NIAID’s topics to Charles Jackson in NIAID’s Office of Acquisitions.
You can also learn more about NIAID Small Business Programs, and contact Natalia Kruchinin for general funding questions.